Abstract

Volume.117 Number.4

Original article : Clinical science

Intravitreal Pegaptanib Sodium for Myopic Choroidal Neovascularization: 1 Year Results of a Prospective Pilot Study
Takako Kitagawa, Mitsuko Yuzawa
Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine

Objective: To evaluate ophthalmologic outcomes 1 year after intravitreal pegaptanib sodium injection in patients with myopic choroidal neovascularization (CNV).
Subjects and Methods: We investigated 31 eyes of 30 patients who had been given intravitreal pegaptanib sodium (0.3 mg) injections for subfoveal or juxtafoveal myopic CNV at 6-week intervals from July through December 2009. We compared visual acuity, retinal sensitivity within the central 12 degrees and maximum lesion diameter, and quantified metamorphopsia using M-CHARTS (Inami Co., Tokyo) both before and after the intravitreal injections. The Wilcoxon test was applied to identify statistically significant differences.
Results: Mean logMAR visual acuity was 0.49±0.38 before and 0.47±0.35 after treatment (p=0.56); the corresponding values for mean retinal sensitivity were 7.48±3.69 dB and 8.15±4.18 dB (p=0.24). Mean maximum lesion diameter was significantly reduced from 1,217 μm to 1,041 μm after treatment (p=0.0021). Mean metamorphopsia scores were significantly improved after treatment, i. e., 0.85±0.68 to 0.50±0.39 for vertical lines (p=0.016); 0.81±0.74 to 0.47±0.41 for horizontal lines (p=0.017). The average number of injections was 3.1. No patient experienced adverse events associated with treatment.
Conclusion: Visual acuity and retinal sensitivity were maintained, while metamorphopsia was improved 1 year after intravitreal pegaptanib sodium injections for myopic CNV.
Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 117: 344-350, 2013.

Key words
Myopic choroidal neovascularization, Pegaptanib sodium, Intravitreal injection, One-year outcome, Maintenance
Reprint requests to
Takako Kitagawa, M.D. Division of Ophthalmology, Department of Visual Sciences, Surugadai-Hospital, Nihon University School of Medicine. 1-8-13 Kanda Surugadai, Chiyoda-ku, Tokyo 101-8309, Japan